TinaMAlbertsonMDPhD
Pediatric Hematology & Oncology • Seattle, WAPediatric Hematologic Oncology
Chief Medical Officer, Drug Development
Dr. Albertson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
307 Westlake Ave N Ste 300
Seattle, WA 98109Phone+1 206-582-1733- Is this information wrong?
Education & Training
University of WashingtonPhD, Cancer Biology, 2005 - 2010
University of WashingtonFellowship, Pediatric Hematology/Oncology, 2002 - 2005
University of ColoradoResidency, Pediatrics, 1999 - 2002
Stanford University School of MedicineClass of 1999
Certifications & Licensure
WA State Medical License 2002 - 2024
Clinical Trials
- A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Start of enrollment: 2016 Jan 06
Publications & Presentations
PubMed
- 1009 citationsLisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon E. Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos ...> ;Lancet. 2020 Sep 19
- 9 citationsA Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.Melanie Quintana, Daniel H. Li, Tina Albertson, Jason T. Connor> ;Contemporary Clinical Trials. 2016 May 1
- 5 citationsBayesian dose escalation in oncology with sharing of information between patient populationsKristine Broglio, Larissa Sandalic, Tina Albertson, Scott M. Berry> ;Contemporary Clinical Trials. 2015 Sep 1
- Join now to see all
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Tina Albertson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological MalignanciesTina Albertson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022September 12th, 2022
Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-cell TherapiesAugust 27th, 2020
Mass. General Team Reports First Response of Central Nervous System Tumor to CAR T-cellsSeptember 1st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
